SG11201601181SA - Improved adenovirus formulations - Google Patents

Improved adenovirus formulations

Info

Publication number
SG11201601181SA
SG11201601181SA SG11201601181SA SG11201601181SA SG11201601181SA SG 11201601181S A SG11201601181S A SG 11201601181SA SG 11201601181S A SG11201601181S A SG 11201601181SA SG 11201601181S A SG11201601181S A SG 11201601181SA SG 11201601181S A SG11201601181S A SG 11201601181SA
Authority
SG
Singapore
Prior art keywords
improved adenovirus
adenovirus formulations
formulations
improved
adenovirus
Prior art date
Application number
SG11201601181SA
Other languages
English (en)
Inventor
Janik Adriaansen
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201601181S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of SG11201601181SA publication Critical patent/SG11201601181SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201601181SA 2013-09-19 2014-09-16 Improved adenovirus formulations SG11201601181SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13185200 2013-09-19
PCT/EP2014/069654 WO2015040002A1 (en) 2013-09-19 2014-09-16 Improved adenovirus formulations

Publications (1)

Publication Number Publication Date
SG11201601181SA true SG11201601181SA (en) 2016-04-28

Family

ID=49212683

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201601181SA SG11201601181SA (en) 2013-09-19 2014-09-16 Improved adenovirus formulations

Country Status (32)

Country Link
US (3) US9974737B2 (ko)
EP (1) EP3046536B1 (ko)
JP (1) JP6013654B2 (ko)
KR (1) KR102258348B1 (ko)
CN (2) CN105530917B (ko)
AP (1) AP2016009154A0 (ko)
AU (1) AU2014323230B2 (ko)
BR (1) BR112016005761B1 (ko)
CA (1) CA2923352C (ko)
CL (1) CL2016000621A1 (ko)
CY (1) CY1122796T1 (ko)
DK (1) DK3046536T3 (ko)
EA (1) EA036046B1 (ko)
ES (1) ES2711115T3 (ko)
HR (1) HRP20182159T1 (ko)
HU (1) HUE041791T2 (ko)
IL (1) IL244572A (ko)
LT (1) LT3046536T (ko)
ME (1) ME03324B (ko)
MX (1) MX369156B (ko)
MY (1) MY181190A (ko)
NZ (1) NZ717156A (ko)
PE (1) PE20160527A1 (ko)
PH (1) PH12016500316A1 (ko)
PL (1) PL3046536T3 (ko)
PT (1) PT3046536T (ko)
RS (1) RS58393B1 (ko)
SG (1) SG11201601181SA (ko)
SI (1) SI3046536T1 (ko)
TR (1) TR201900274T4 (ko)
WO (1) WO2015040002A1 (ko)
ZA (1) ZA201601919B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
WO2015038958A1 (en) 2013-09-13 2015-03-19 California Institute Of Technology Selective recovery
BR112016005761B1 (pt) 2013-09-19 2022-09-20 Janssen Vaccines & Prevention B.V Formulação de adenovírus, e, método de preservação de um adenovírus
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CA3001050C (en) * 2015-10-06 2023-03-28 Janssen Vaccines & Prevention B.V. Method for preventing surface-induced degradation of viruses using cyclodextrins
AU2016366549B2 (en) 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
HUE053027T2 (hu) 2016-04-05 2021-06-28 Janssen Vaccines & Prevention Bv Stabilizált, szolúbilis prefúziós RSV F fehérje, RSV-fertõzés megelõzésében történõ alkalmazásra
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
ES2836598T3 (es) 2016-05-30 2021-06-25 Janssen Vaccines & Prevention Bv Proteínas F de RSV prefusión estabilizadas
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EA202090738A1 (ru) 2017-09-15 2020-06-10 Янссен Вэксинс Энд Превеншн Б.В. Способ безопасного индуцирования иммунитета против rsv
WO2020068990A1 (en) 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
WO2020145872A1 (en) * 2019-01-09 2020-07-16 Ziccum Ab Stabilized non-enveloped virus compositions
MX2024000472A (es) * 2021-07-08 2024-02-12 Biocad Joint Stock Co Composicion farmaceutica de virus no encapsulado.
WO2023240196A1 (en) * 2022-06-08 2023-12-14 Gritstone Bio, Inc. Compositions and methods of use thereof
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations
WO2024079657A1 (en) * 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Formulations for aav gene therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DE69940354D1 (de) 1998-11-16 2009-03-12 Introgen Therapeutics Inc Adenovirus-formulierungen zur gentherapie
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1263461A4 (en) * 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
CA2469491A1 (en) * 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
US20030170216A1 (en) * 2001-12-20 2003-09-11 Schering-Plough Corporation SYN3 compositions and methods
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
EA010828B1 (ru) 2002-04-25 2008-12-30 Круселл Холланд Б.В. Рекомбинантный аденовирусный вектор и способы его получения и применения
NZ539813A (en) 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
NZ543970A (en) 2003-06-04 2008-09-26 Canji Inc Methods and compositions for interferon therapy
WO2005012407A2 (en) * 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
WO2005052116A2 (en) * 2003-11-19 2005-06-09 Merck & Co., Inc. Preservative-containing virus formulations
WO2005085427A1 (ja) 2004-03-04 2005-09-15 Dainippon Sumitomo Pharma Co., Ltd. ラット胚性幹細胞
CN102220357B (zh) 2004-11-16 2013-12-25 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
CN1883707A (zh) * 2006-05-19 2006-12-27 吉林大学 重组腺病毒的冻干制剂及其制备方法
GB0715723D0 (en) * 2007-08-11 2007-09-19 Ark Therapeutics Ltd Formulation
WO2011028962A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
GB201002419D0 (en) 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
EA201391043A1 (ru) 2011-02-17 2014-03-31 Сентисс Фарма Прайвет Лимитед Способ и композиция для замедления сорбции консервантов пластиками
BR112016005761B1 (pt) * 2013-09-19 2022-09-20 Janssen Vaccines & Prevention B.V Formulação de adenovírus, e, método de preservação de um adenovírus
CN104027815A (zh) 2014-06-12 2014-09-10 中国农业科学院兰州畜牧与兽药研究所 一种丹参酮包合液及其制备方法和应用
CA3001050C (en) 2015-10-06 2023-03-28 Janssen Vaccines & Prevention B.V. Method for preventing surface-induced degradation of viruses using cyclodextrins

Also Published As

Publication number Publication date
HRP20182159T1 (hr) 2019-02-22
MY181190A (en) 2020-12-21
US11484494B2 (en) 2022-11-01
PE20160527A1 (es) 2016-05-20
ME03324B (me) 2019-10-20
PH12016500316B1 (en) 2016-05-02
BR112016005761B1 (pt) 2022-09-20
DK3046536T3 (en) 2019-03-11
LT3046536T (lt) 2019-03-12
CA2923352A1 (en) 2015-03-26
EP3046536A1 (en) 2016-07-27
IL244572A0 (en) 2016-04-21
JP6013654B2 (ja) 2016-10-25
ES2711115T3 (es) 2019-04-30
CY1122796T1 (el) 2021-05-05
US9974737B2 (en) 2018-05-22
JP2016530220A (ja) 2016-09-29
EA036046B1 (ru) 2020-09-18
MX2016003414A (es) 2016-06-30
US20180235871A1 (en) 2018-08-23
AU2014323230A1 (en) 2016-03-17
RS58393B1 (sr) 2019-04-30
IL244572A (en) 2017-02-28
AU2014323230B2 (en) 2017-05-25
PL3046536T3 (pl) 2019-06-28
KR102258348B1 (ko) 2021-05-31
CN105530917A (zh) 2016-04-27
PT3046536T (pt) 2019-02-25
ZA201601919B (en) 2017-06-28
US20160199426A1 (en) 2016-07-14
BR112016005761A2 (ko) 2017-08-01
HUE041791T2 (hu) 2019-05-28
US20190240146A1 (en) 2019-08-08
AP2016009154A0 (en) 2016-04-30
WO2015040002A1 (en) 2015-03-26
MX369156B (es) 2019-10-30
US10272032B2 (en) 2019-04-30
EA201690613A1 (ru) 2016-08-31
EP3046536B1 (en) 2018-11-28
CA2923352C (en) 2022-05-03
TR201900274T4 (tr) 2019-02-21
NZ717156A (en) 2022-04-29
SI3046536T1 (sl) 2019-05-31
KR20160055180A (ko) 2016-05-17
PH12016500316A1 (en) 2016-05-02
CN105530917B (zh) 2020-06-05
CL2016000621A1 (es) 2016-11-25
CN111514314A (zh) 2020-08-11

Similar Documents

Publication Publication Date Title
HRP20182159T1 (hr) Poboljšane formulacije adenovirusa
EP3065716C0 (en) FORMULATIONS
IL240723A0 (en) A vaccine
HK1219061A1 (zh) 乳液製劑
PT3071638T (pt) Composição de cianoacrilato
SG11201507393TA (en) Oncolytic adenovirus compositions
GB201319792D0 (en) Formulations
EP2961397A4 (en) TRANSDERMAL FORMULATIONS
HK1224228A1 (zh) 新型製劑
HK1214951A1 (zh) 眼用製劑
GB201320432D0 (en) Novel formulation
EP2999689A4 (en) CYANOACRYLATE COMPOSITIONS
SG11201509194SA (en) Radiomitigating pharmaceutical formulations
HK1220366A1 (zh) 蛋白製劑
GB201322948D0 (en) Improved formulation
GB2517232B (en) Formulation
GB201317718D0 (en) Novel formulation
GB201313688D0 (en) Improved cyanoacrylate compositions
SG11201604136PA (en) Improved formulations for virosomes
PT3041488T (pt) Composições de mel
GB201318885D0 (en) Adenovirus
GB201318880D0 (en) Adenovirus
HK1209981A1 (en) Formulation
EP2986109A4 (en) IMPROVED ECTOPARASITICIDE FORMULATIONS
GB201317717D0 (en) Novel formulation